Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5489-5500

  He, Xi ^a   Zhao, Ming ^a   Bi, Xueyuan ^a   Sun, Lei ^a   Yu, Xiaojiang ^a   Zhao, Mei ^a   Zang, Weijin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PRAVASTATIN; PYRIDOSTIGMINE; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; EXERCISE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; IMPLANTABLE NEUROSTIMULATOR; MITOCHONDRIAL PERMEABILITY; NEUROMODULATION; NONHUMAN; OXIDATION REDUCTION STATE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; REVIEW; VAGUS NERVE STIMULATION; VAGUS TONE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; VAGUS NERVE;

CARDIOVASCULAR DISEASES; HUMANS; VAGUS NERVE;

EID: 84949535666     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13010     Document Type: Review

References (112)

1. Abboud FM, (2010). The Walter B. Cannon Memorial Award Lecture. Physiology in perspective: the wisdom of the body. In search of autonomic balance: the good, the bad, and the ugly. Am J Physiol Regul Integr Comp Physiol 298: R1449-R1467.
2. Abboud FM, Harwani SC, Chapleau MW, (2012). Autonomic neural regulation of the immune system: implications for hypertension and cardiovascular disease. Hypertension 59: 755-762.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-Gated Ion Channels. Br J Pharmacol 170: 1582-1606.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Barbosa Neto O, Abate DT, Marocolo Júnior M, Mota GR, Orsatti FL, Rossi e Silva RC, et al. (2013). Exercise training improves cardiovascular autonomic activity and attenuates renal damage in spontaneously hypertensive rats. J Sports Sci Med 12: 52-59.
7. Beny JL, Nguyen MN, Marino M, Matsui M, (2008). Muscarinic receptor knockout mice confirm involvement of M3 receptor in endothelium-dependent vasodilatation in mouse arteries. J Cardiovasc Pharmacol 51: 505-512.
8. Bernardi L, Porta C, Spicuzza L, Bellwon J, Spadacini G, Frey AW, et al. (2002). Slow breathing increases arterial baroreflex sensitivity in patients with chronic heart failure. Circulation 105: 143-145.
9. Bi XY, He X, Zhao M, Yu XJ, Zang WJ, (2013). Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury. J Cardiovasc Pharmacol 61: 391-400.
10. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405: 458-462.
11. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM, (2005). Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail 11: 693-699.
12. Calvillo L, Vanoli E, Andreoli E, Besana A, Omodeo E, Gnecchi M, et al. (2011). Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J Cardiovasc Pharmacol 58: 500-507.
13. Cooke JP, Ghebremariam YT, (2008). Endothelial nicotinic acetylcholine receptors and angiogenesis. Trends Cardiovasc Med 18: 247-253.
14. De Couck M, van Brummelen D, Schallier D, De Grève J, Gidron Y, (2013). The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. Oncol Rep 30: 2435-2441.
15. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M, et al. (2011). Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 32: 847-855.
16. Dicarlo L, Libbus I, Amurthur B, Kenknight BH, Anand IS, (2013). Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: the ANTHEM-HF study. J Card Fail 19: 655-660.
17. Dromparis P, Michelakis ED, (2013). Mitochondria in vascular health and disease. Annu Rev Physiol 75: 95-126.
18. Durand MT, Becari C, de Oliveira M, do Carmo JM, Silva CA, Prado CM, et al. (2014). Pyridostigmine restores cardiac autonomic balance after small myocardial infarction in mice. PLoS ONE 9: e104476.
19. Erin N, Duymuş O, Oztürk S, Demir N, (2012). Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis. Regul Pept 179: 101-108.
20. Floras JS, (2009). Sympathetic nervous system: clinical implications of an updated model. J Am Coll Cardiol 54: 375-385.
21. Gavioli M, Lara A, Almeida PW, Lima AM, Damasceno DD, Rocha-Resende C, et al. (2014). Cholinergic signaling exerts protective effects in models of sympathetic hyperactivity-induced cardiac dysfunction. PLoS ONE 9: e100179.
22. Gericke A, Sniatecki JJ, Mayer VG, Goloborodko E, Patzak A, Wess J, et al. (2011). Role of M1, M3, and M5 muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice. Am J Physiol Heart Circ Physiol 300: H1602-H1608.
23. Gidron Y, De Couck M, De Greve J, (2014). If you have an active vagus nerve, cancer stage may no longer be important. J Biol Regul Homeost Agents 28: 195-201.
24. Gong X, Ma Y, Ruan Y, Fu G, Wu S, (2014). Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exp Gerontol 52: 9-17.
25. Groschner LN, Waldeck-Weiermair M, Malli R, Graier WF, (2012). Endothelial mitochondria-less respiration, more integration. Pflugers Arch 464: 63-76.
26. Guiraud T, Labrunee M, Gaucher-Cazalis K, Despas F, Meyer P, Bosquet L, et al. (2013). High-intensity interval exercise improves vagal tone and decreases arrhythmias in chronic heart failure. Med Sci Sports Exerc 45: 1861-1867.
27. Hamann JJ, Ruble SB, Stolen C, Wang M, Gupta RC, Rastogi S, et al. (2013). Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. Eur J Heart Fail 15: 1319-1326.
28. Harvey RD, (2012). Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol 208: 299-316.
29. He X, Zhang HL, Zhao M, Yang JL, Cheng G, Sun L, et al. (2011). Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 38: 255-261.
30. He X, Zhao M, Bi XY, Yu XJ, Zang WJ, (2013). Delayed preconditioning prevents ischemia/reperfusion-induced endothelial injury in rats: role of ROS and eNOS. Lab Invest 93: 168-180.
31. Huston JM, Tracey KJ, (2011). The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. J Intern Med 269: 45-53.
32. Johnston GR, Webster NR, (2009). Cytokines and the immunomodulatory function of the vagus nerve. Br J Anaesth 102: 453-462.
33. de Jonge WJ, Ulloa L, (2007). The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151: 915-929.
34. Joseph CN, Porta C, Casucci G, Casiraghi N, Maffeis M, Rossi M, et al. (2005). Slow breathing improves arterial baroreflex sensitivity and decreases blood pressure in essential hypertension. Hypertension 46: 714-718.
35. Joyner MJ, Green DJ, (2009). Exercise protects the cardiovascular system: effects beyond traditional risk factors. J Physiol 587: 5551-5558.
36. Katare RG, Ando M, Kakinuma Y, Arikawa M, Handa T, Yamasaki F, et al. (2009). Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. J Thorac Cardiovasc Surg 137: 223-231.
37. Kawada T, Akiyama T, Shimizu S, Kamiya A, Uemura K, Li M, et al. (2009). Detection of endogenous acetylcholine release during brief ischemia in the rabbit ventricle: a possible trigger for ischemic preconditioning. Life Sci 85: 597-601.
38. Kim MH, Kim MO, Heo JS, Kim JS, Han HJ, (2008). Acetylcholine inhibits long-term hypoxia-induced apoptosis by suppressing the oxidative stress-mediated MAPKs activation as well as regulation of Bcl-2, c-IAPs, and caspase-3 in mouse embryonic stem cells. Apoptosis 13: 295-304.
39. Kluge MA, Fetterman JL, Vita JA, (2013). Mitochondria and endothelial function. Circ Res 112: 1171-1188.
40. Kong SS, Liu JJ, Hwang TC, Yu XJ, Lu Y, Zang WJ, (2011). Tumour necrosis factor-α and its receptors in the beneficial effects of vagal stimulation after myocardial infarction in rats. Clin Exp Pharmacol Physiol 38: 300-306.
41. Kong SS, Liu JJ, Yu XJ, Lu Y, Zang WJ, (2012a). Protection against ischemia-induced oxidative stress conferred by vagal stimulation in the rat heart: involvement of the AMPK-PKC Pathway. Int J Mol Sci 13: 14311-14325.
42. Kong SS, Liu JJ, Hwang TC, Yu XJ, Zhao M, Zhao M, et al. (2012b). Optimizing the parameters of vagus nerve stimulation by uniform design in rats with acute myocardial infarction. PLoS ONE 7: e42799.
43. Kruse AC, Kobilka BK, Gautam D, Sexton PM, Christopoulos A, Wess J, (2014). Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev Drug Discov 13: 549-560.
44. Kusunose K, Zhang Y, Mazgalev TN, Van Wagoner DR, Thomas JD, Popovic ZB, (2014). Impact of vagal nerve stimulation on left atrial structure and function in a canine high-rate pacing model. Circ Heart Fail 7: 320-326.
45. La Rovere MT, Bersano C, Gnemmi M, Specchia G, Schwartz PJ, (2002). Exercise-induced increase in baroreflex sensitivity predicts improved prognosis after myocardial infarction. Circulation 106: 945-949.
46. La Rovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, et al. (2009). Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol 53: 193-199.
47. La Rovere MT, Pinna GD, Maestri R, Sleight P, (2013). Clinical value of baroreflex sensitivity. Neth Heart J 21: 61-63.
48. Lamping KG, Wess J, Cui Y, Nuno DW, Faraci FM, (2004). Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol 24: 1253-1258.
49. Lataro RM, Silva CA, Fazan R Jr, Rossi MA, Prado CM, Godinho RO, et al. (2013). Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. Am J Physiol Regul Integr Comp Physiol 305: R908-R916.
50. Lei J, Vodovotz Y, Tzeng E, Billiar TR, (2013). Nitric oxide, a protective molecule in the cardiovascular system. Nitric Oxide 35: 175-185.
51. Li DL, Liu JJ, Liu BH, Hu H, Sun L, Miao Y, et al. (2011). Acetylcholine inhibits hypoxia-induced tumor necrosis factor-α production via regulation of MAPKs phosphorylation in cardiomyocytes. J Cell Physiol 226: 1052-1059.
52. Li M, Zheng C, Kawada T, Inagaki M, Uemura K, Sugimachi M, (2014). Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. Eur J Heart Fail 16: 1056-1065.
53. Li PC, Li SC, Lin YJ, Liang JT, Chien CT, Shaw CF, (2005). Thoracic vagal efferent nerve stimulation evokes substance P-induced early airway bronchonstriction and late proinflammatory and oxidative injury in the rat respiratory tract. J Biomed Sci 12: 671-681.
54. Li XW, Wang H, (2006). Non-neuronal nicotinic alpha 7 receptor, a new endothelial target for revascularization. Life Sci 78: 1863-1870.
55. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. (2008). A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14: 510-517.
56. Liu C, Su D, (2012). Nicotinic acetylcholine receptor α7 subunit: a novel therapeutic target for cardiovascular diseases. Front Med 6: 35-40.
57. Liu JJ, Li DL, Zhou J, Sun L, Zhao M, Kong SS, et al. (2011). Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells. Apoptosis 16: 94-103.
58. Liu Y, Sun L, Pan Z, Bai Y, Wang N, Zhao J, et al. (2011). Overexpression of m(3) muscarinic receptors is a novel strategy for preventing sudden cardiac death in transgenic mice. Mol Med 17: 1179-1187.
59. Lorin J, Zeller M, Guilland JC, Cottin Y, Vergely C, Rochette L, (2014). Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects. Mol Nutr Food Res 58: 101-116.
60. Lu B, Kwan K, Levine YA, Olofsson PS, Yang H, Li J, et al. (2014). α7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release. Mol Med 20: 350-358.
61. Lu J, Zang WJ, Yu XJ, Jia B, Chorvatova A, Sun L, (2006). Effects of postconditioning of adenosine and acetylcholine on the ischemic isolated rat ventricular myocytes. Eur J Pharmacol 549: 133-139.
62. Lu X, Costantini T, Lopez NE, Wolf PL, Hageny AM, Putnam J, et al. (2013). Vagal nerve stimulation protects cardiac injury by attenuating mitochondrial dysfunction in a murine burn injury model. J Cell Mol Med 17: 664-671.
63. Lu Y, Liu JJ, Bi XY, Yu XJ, Kong SS, Qin FF, et al. (2014). Pyridostigmine ameliorates cardiac remodeling induced by myocardial infarction via inhibition of the transforming growth factor-β1/TGF-β1-activated kinase pathway. J Cardiovasc Pharmacol 63: 412-420.
64. Marks AR, (2013). Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 123: 46-52.
65. Mason H, Vandoni M, Debarbieri G, Codrons E, Ugargol V, Bernardi L, (2013). Cardiovascular and respiratory effect of yogic slow breathing in the yoga beginner: what is the best approach? Evid Based Complement Alternat Med 2013: 743504.
66. Miao Y, Zhou J, Zhao M, Liu J, Sun L, Yu X, et al. (2013). Acetylcholine attenuates hypoxia/ reoxygenation-induced mitochondrial and cytosolic ROS formation in H9c2 cells via M2 acetylcholine receptor. Cell Physiol Biochem 31: 189-198.
67. Miao Y, Bi XY, Zhao M, Jiang HK, Liu JJ, Li DL, et al. (2014). Acetylcholine inhibits tumor necrosis factor α activated endoplasmic reticulum apoptotic pathway via EGFR-PI3K signaling in cardiomyocytes. J Cell Physiol. doi: 10.1002/jcp.24800; [Epub ahead of print].
68. Morello F, Perino A, Hirsch E, (2009). Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc Res 82: 261-271.
69. Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F, (2000). Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 36: 1612-1618.
70. Ni M, Yang ZW, Li DJ, Li Q, Zhang SH, Su DF, et al. (2010). A potential role of alpha-7 nicotinic acetylcholine receptor in cardiac angiogenesis in a pressure-overload rat model. J Pharmacol Sci 114: 311-319.
71. Oldenburg O, Critz SD, Cohen MV, Downey JM, (2003). Acetylcholine-induced production of reactive oxygen species in adult rabbit ventricular myocytes is dependent on phosphatidylinositol 3-and Src-kinase activation and mitochondrial K(ATP) channel opening. J Mol Cell Cardiol 35: 653-660.
72. Paillard M, Tubbs E, Thiebaut PA, Gomez L, Fauconnier J, Da Silva CC, et al. (2013). Depressing mitochondria-reticulum interactions protects cardiomyocytes from lethal hypoxia-reoxygenation injury. Circulation 128: 1555-1565.
73. Pal GK, Pal P, Nanda N, Amudharaj D, Adithan C, (2013). Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: physiological perspectives. Future Cardiol 9: 53-69.
74. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-1106.
75. Payrits T, Ernst A, Ladits E, Pokorny H, Viragos I, Langle F, (2011). Vagal stimulation-a new possibility for conservative treatment of peripheral arterial occlusion disease. Zentralbl Chir 136: 431-435.
76. - mice in vivo. Circulation 107: 2480-2486.
77. Piccirillo G, Luparini RL, Celli V, Moisè A, Lionetti M, Marigliano V, et al. (2000). Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. Am J Cardiol 86: 1392-1395, A6.
78. Pliquett R, Cornish K, Zucker I, (2003). Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 95: 700-704.
79. Qin F, Lu Y, He X, Zhao M, Bi X, Yu X, et al. (2014). Pyridostigmine prevents peripheral vascular endothelial dysfunction in rats with myocardial infarction. Clin Exp Pharmacol Physiol 41: 202-209.
80. Sabbah HN, Imai M, Zaretsky A, Rastogi S, Wang M, Jiang A, (2007). Therapy with vagus nerve electrical stimulation combined with beta-blockade improves left ventricular systolic function in dogs with heart failure beyond that seen with beta-blockade alone. Eur J Heart Fail 6 (Suppl. 1): 114.
81. Sant'Ana JE, Pereira MG, Dias da Silva VJ, Dambrõs C, Costa-Neto CM, Souza HC, (2011). Effect of the duration of daily aerobic physical training on cardiac autonomic adaptations. Auton Neurosci 159: 32-37.
82. Schwartz PJ, (2011). Vagal stimulation for heart diseases: from animals to men. An example of translational cardiology. Circ J 75: 20-27.
83. Schwartz PJ, De Ferrari GM, Sanzo A, Landolina M, Rordorf R, Raineri C, et al. (2008). Long term vagal stimulation in patients with advanced heart failure: first experience in man. Eur J Heart Fail 10: 884-891.
84. Searl TJ, Silinsky EM, (2003). Phorbol esters and adenosine affect the readily releasable neurotransmitter pool by different mechanisms at amphibian motor nerve endings. J Physiol 553: 445-456.
85. Soares-Miranda L, Sandercock G, Valente H, Vale S, Santos R, Mota J, (2009). Vigorous physical activity and vagal modulation in young adults. Eur J Cardiovasc Prev Rehabil 16: 705-711.
86. Sun L, Li DL, Zhao M, He X, Yu XJ, Miao Y, et al. (2011a). The role of muscarinic receptors in the beneficial effects of adenosine against myocardial reperfusion injury in rats. PLoS ONE 6: e25618.
87. Sun L, Lu J, Yu XJ, Li DL, Xu XL, Wang B, et al. (2011b). Adenine sulfate improves cardiac function and the cardiac cholinergic system after myocardial infarction in rats. J Pharmacol Sci 115: 205-213.
88. Sun L, Zhao M, Yu XJ, Wang H, He X, Liu JK, et al. (2013). Cardioprotection by acetylcholine: a novel mechanism via mitochondrial biogenesis and function involving the PGC-1α pathway. J Cell Physiol 228: 1238-1248.
89. Talukder MA, Zweier JL, Periasamy M, (2009). Targeting calcium transport in ischaemic heart disease. Cardiovasc Res 84: 345-352.
90. Tang X, Luo YX, Chen HZ, Liu DP, (2014). Mitochondria, endothelial cell function, and vascular diseases. Front Physiol 5: 175.
91. Tracey KJ, (2007). Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117: 289-296.
92. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J, (2009). The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 54: 1747-1762.
93. Tsai MW, Chie WC, Kuo TB, Chen MF, Liu JP, Chen TT, et al. (2006). Effects of exercise training on heart rate variability after coronary angioplasty. Phys Ther 86: 626-635.
94. Tsuboi M, Chiba S, (2003). Adenosine infusion inhibits adenosine-induced cardiac actions but enhances acetylcholine-induced actions in isolated dog atria. Heart Vessels 18: 26-31.
95. Tsutsumi T, Ide T, Yamato M, Kudou W, Andou M, Hirooka Y, et al. (2008). Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction. Cardiovasc Res 77: 713-721.
96. Uemura K, Zheng C, Li M, Kawada T, Sugimachi M, (2010). Early short-term vagal nerve stimulation attenuates cardiac remodeling after reperfused myocardial infarction. J Card Fail 16: 689-699.
97. Vrtovec B, Okrajsek R, Golicnik A, Ferjan M, Starc V, Radovancevic B, (2005). Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 11: 684-690.
98. Walters AM, Porter GA Jr, Brookes PS, (2012). Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 111: 1222-1236.
99. Wang S, Han H, Jiang Y, Wang C, Song H, Pan Z, et al. (2012a). Activation of cardiac M3 muscarinic acetylcholine has cardioprotective effects against ischemia-induced arrhythmias. Clin Exp Pharmacol Physiol 39: 343-349.
100. Wang S, Han HM, Pan ZW, Hang PZ, Sun LH, Jiang YN, et al. (2012b). Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. Naunyn Schmiedebergs Arch Pharmacol 385: 823-831.
101. Wang YH, Hu H, Wang SP, Tian ZJ, Zhang QJ, Li QX, et al. (2010). Exercise benefits cardiovascular health in hyperlipidemia rats correlating with changes of the cardiac vagus nerve. Eur J Appl Physiol 108: 459-468.
102. Welzig CM, Shin DG, Park HJ, Kim YH, Saul JP, Galper JB, (2003). Lipid lowering by pravastatin increases parasympathetic modulation of heart rate. Circulation 108: 2743-2746.
103. Wessler I, Kirkpatrick CJ, (2008). Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 154: 1558-1571.
104. Woodman OL, (1989). Noradrenaline-induced constriction of large and small coronary arteries in the anaesthetized dog. J Auton Pharmacol 9: 53-61.
105. Wu L, Jiang Z, Li C, Shu M, (2014). Prediction of heart rate variability on cardiac sudden death in heart failure patients: a systematic review. Int J Cardiol 174: 857-860.
106. Xiong J, Yuan YJ, Xue FS, Wang Q, Cheng Y, Li RP, et al. (2012). Postconditioning with α7nACh receptor agonist attenuates systemic inflammatory response to myocardial ischemia-reperfusion injury in rats. Inflammation 35: 1357-1364.
107. Xu XL, Zang WJ, Lu J, Kang XQ, Li M, Yu XJ, (2006). Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart. Auton Neurosci 130: 6-16.
108. Yang B, Lin H, Xu C, Liu Y, Wang H, Han H, (2005). Choline produces cytoprotective effects against ischemic myocardial injuries: evidence for the role of cardiac m3 subtype muscarinic acetylcholine receptors. Cell Physiol Biochem 16: 163-174.
109. Zhang YH, Jin CZ, Jang JH, Wang Y, (2014). Molecular mechanisms of neuronal nitric oxide synthase in cardiac function and pathophysiology. J Physiol 592: 3189-3200.
110. Zhao J, Su Y, Zhang Y, Pan Z, Yang L, Chen X, et al. (2010). Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up-regulating cyclooxygenase-2 expression. Br J Pharmacol 159: 1217-1325.
111. Zhao M, He X, Bi XY, Yu XJ, Gil Wier W, Zang WJ, (2013a). Vagal stimulation triggers peripheral vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion. Basic Res Cardiol 108: 345.
112. Zhao M, Sun L, Yu XJ, Miao Y, Liu JJ, Wang H, et al. (2013b). Acetylcholine mediates AMPK-dependent autophagic cytoprotection in H9c2 cells during hypoxia/reoxygenation injury. Cell Physiol Biochem 32: 601-613.